芦可替尼乳膏对白癜风有效吗?

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

Ruxolitinib cream is effective for vitiligo

Ruxolitinib cream reduces inflammation and itching symptoms by inhibiting cytokine signaling pathways, thereby promoting the healing of damaged skin. It is an effective drug for the treatment of skin diseases such as vitiligo. Ruxolitinib cream reduces inflammatory factors in the skin by inhibiting the JAK signaling pathway, thereby reducing damage to melanocytes, promoting the synthesis and transfer of melanin, and improving the color and area of white spots. It is mainly suitable for the treatment of non-segmental vitiligo (NSV) in adults and children (12 years and above).

The experimental effect of ruxolitinib cream in the treatment of vitiligo

Vitiligo is a chronic autoimmune disease that causes loss of skin pigmentation. In a phase 2 trial involving adults with vitiligo, ruxolitinib cream re-pigmented the skin.

research methods

Two Phase 3, double-blind, vehicle-controlled trials (Topical Ruxolitinib Cream in Vitiligo Evaluation Study 1 [TRuE-V1, NCT04052425] and 2 [TRuE-V2, NCT04057573]) were conducted in North America and Europe in patients 12 years of age or older with nonsegmental vitiligo and depigmentation of 10% or less of the total body surface area.

Patients were randomly assigned in a 2:1 ratio to all areas of vitiligo on the face and body to apply ruxolitinib 1.5% cream or control twice daily for 24 weeks, after which all patients could apply ruxolitinib 1.5% cream until week 52. The primary endpoint was a decrease (improvement) of at least 75% from baseline in the Facial Vitiligo Area Score Index (F-VASI; ranging from 0 to 3, with higher scores indicating greater facial depigmentation) at week 24, an F-VASI75 response. There were five key secondary endpoints, including improved response on the Vitiligo Noticeability Scale.

Test results

A total of 674 patients were enrolled, 330 in TRuE-V1 and 344 in TRuE-V2. In TRuE-V1, the proportion of patients with an F-VASI75 response at week 24 was 29.8% in the ruxolitinib cream group and 7.4% in the vehicle group (relative risk, 4.0).

In TRuE-V2, the proportions were 30.9% and 11.4% (relative risk 2.7). Results on key secondary endpoints showed ruxolitinib cream was superior to the drug control group.

Among patients who used ruxolitinib cream for 52 weeks, 54.8% and 62.3% of patients with TRuE-V1 and TRuE-V2 experienced adverse events; the most common were application site acne (6.3% and 6.6%, respectively), nasopharyngitis (5.4% and 6.1%, respectively), and application site pruritus (5.4% and 5.3%, respectively).

Test conclusion

In two phase 3 trials, the degree of repigmentation of vitiligo lesions after 52 weeks of ruxolitinib cream was greater than that in the drug control group, but was associated with acne and application site pruritus.

ruxolitinib cream price

At present, the price of ruxolitinib cream is roughly as follows through domestic professional overseas medical service organizations (such as Medical Travel):

1. Yaopin International mails ruxolitinib ointment 30mg from Yunda in Hong Kong, China. The price is about 559$ per box;

2. The price of the postal version of ruxolitinib ointment in Bangladesh is about $480 per box;

3. The direct mail price of ruxolitinib ointment from Hong Kong, China is about $20,700 per box.

At present, ruxolitinib cream is not available in mainland China, and it is not available in hospital pharmacies in mainland China. Patients in need can obtain it through domestic professional overseas medical service organizations (such as Medical Companion Travel). The drugs can be mailed to their homes, which is guaranteed to be authentic and more cost-effective. However, the price is subject to various factors and is not fixed. It is recommended to consult customer service personnel for specific costs and acquisition procedures.

Menu